Abstract 22P
Background
The purpose of this study was to evaluate the characteristics and outcomes of early breast cancer patients who underwent skin-sparing mastectomy or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy without radiotherapy.
Methods
A total 104 patients with early breast cancer who underwent mastectomy with sentinel lymph node biopsy were identified in Korea Ansan University Hospital between 2007 and 2017. 85 total mastectomies (TM), 11 nipple areolar complex-sparing mastectomies (NSM), and 8 Skin-sparing mastectomiesm (SSM) were included. All these patients did not undergo adjuvant radiotherapy on chest wall or axillary area. We divided the patients into two groups, TM group and NSM/SSM group. We retrospectively collected clinitopathologic data for these patients. Locoregional recurrence rate, distant recurrence rate, overall recurrence free survival, and overall survival were determined. All statistical analysis was performed using SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA).
Results
Median follow-up was 53 months. Fifty-five percentage of TM group patients received chemotherapy and 63.7 % of NSM/SSM patients received chemotherapy. Locoregional recurrence free survival was 95.3% vs. 78.9% in TM group and NSM/SSM group (p = 0.037). Locoregional failure rate was significantly high in NSM/SSM group than TM group. Distant recurrence free survival was 97.6% vs. 89.5% in TM group and NSM/SSM group (p = 0.128). Overall recurrence free survival was 92.9% vs. 78.9% in TM group and NSM/SSM group (p = 0.118). Overall survival was 98.8% and 94.7% in TM group and NSM/SSM group (p = 0.289). Total two deaths were observed in enrolled patients, one in TM group and another in NSM/SSM group. One death in TM group was unrelated to breast cancer and cause of death was complication from end-stage renal disease. One death in NSM/SSM group was related to breast cancer.
Conclusions
In conclusion, early breast cancer patients who underwent total mastectomy, skin-sparing mastectomy or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy had excellent outcomes without additional axillary surgery or radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract